Jupiter Neurosciences initiated with a Buy at Greenridge

Greenridge initiated coverage of Jupiter Neurosciences (JUNS) with a Buy rating and $30 price target Despite recently going public at $4.00 per share, the firm believes the value of the company’s resveratrol-based Jotrol platform is “significantly undervalued,” the analyst tells investors. Greenridge believes the company will continue to “aggressively pursue” grant and other non-dilutive funding opportunities to move its pipeline along, while looking into other areas, such as Traditional Chinese Medicine, to generate near-term cash flow.